MURAT GÜNAY, SEVİLAY TOPCUOĞLU, Gökhan ÇELİK, Tuğba GÜRSOY

Prematüre Retinopatisi: Sıklık Azalıyor mu?

Amaç: Kliniğimizde takip ettiğimiz prematüre olgularda prematüre retinopatisi sıklığını ortaya koymak Materyal-Metod: Kasım 2011- Haziran 2013 tarihleri arasında Zeynep Kamil Kadın ve Çocuk Hastalıkları Eğitim ve Araştırma Hastanesi göz hastalıkları polikliniğine dış merkezlerden refere edilen veya aynı hastanenin yeni doğan yoğun bakım ünitesinde takip edilen toplam 620 prematüre bebeğin dosyaları geriye dönük olarak incelendi. Doğum haftası, doğum ağırlığı, hastalığa ait bulgular (hastalık zonu, evresi), tedavi edilen olgulara ait bulgular (tedavi şekli, tedavi edildiği postmenstrüel hafta) gibi özellikler kaydedildi. Bulgular: Çalışmaya katılan bebeklerin 320si (% 51.6) erkek, 300ü (% 48.4) kız idi. Olguların ortalama doğum haftası 31,21±2,61hf (24-34) ve ortalama doğum ağırlığı1645,17±552,03 gr (470- 3870) idi.Toplam 620 bebeğin 314 ünde (% 50.6) çeşitli evrelerde prematüre retinopatisi (evre 1-3) saptandı. Toplamda 84 (% 13.5) bebekte yüksek riskli eşik öncesi prematüre retinopatisi tespit edilip, bu bebeklere lazer fotokoagulasyonveyaintravitrealanti VEGF tedavileri uygulandı.Prematüre retinopatisi gelişimi ile doğum haftası ve doğum ağırlığı arasında anlamlı derecede ters bir ilişki mevcuttu (p

Retinopathy of Prematurity: Is there a Decline in Incidence

Objective: Toreportthefrequency of retinopathy of prematurityamongprematureinfants in ourclinic Methods:Medical records of 620 prematurebabies who had been referred to Zeynep Kamil Maternity and Childrens Training and Research Hospital for retinopathy of prematurity screening fromouter centers or who had been managed in neonatal intensive care unit at the same hospitalwere investigated retrospectively. Characteristics of infants as gestationalage, birth weight, findings pertaining to retinopathy of prematurity (disease zone and stage), findings of treated cases (treatment modality, postmenstrualage at treatment time) were recorded. Results: Three hundred-twenty (51.6%) of patients were male, 300 (48.4%) were female. Meangestationalage of infants was 31,21±2,61 weeks (24- 34) and mean birth weight was 1645,17±552,03 grams (470-3870). Several stages of retinopathy of prematurity (stage1-3) was detected in 314 (50.6%) of 620 babies during the follow-upperiod. High risk prethres hold retinopathy of prematurity was detected in 84 (13.5%) babies and laserphotocoagulation or intravitrealanti VEGF therapy was applied to the seinfants. There was a significantin versecorrelation between the development of retinopathy of prematurity with gestational age and birth weight. Conclusion: Early gestational ageand low birthweight are thet womost important parameters in development of retinopathy of prematurity. Visual outcomes are better in cases which are treated appropriately and timely.

PDF

___

1. FiersonWM; American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; AmericanAssociation for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013;131(1):189-95
2. Sarıcı SÜ,MutluFM,AltınsoyHİ. Prematüre retinopatisi. Çocuk SagligiHast.Derg. 2008;51:51-61.
3. Altan T, Ovalı F, Eser İ, Uysal S, Acar N, Atay E, Ünver YB, Kapran Z. Yenidoğan yo- ğun bakım ünitesinde taranan bebeklerde prematüre retinopatisi sıklığı ve ilişkili faktörler. Ret-Vit. 2008;16:269-72.
4. ReynoldsJD, HardyRJ, Kennedy KA, Spencer R, van Heuven WA, Fielder AR; Light Reduction in Retinopathy of Prematurity (LIGHT-ROP) Cooperative Group. Lack of efficacy of light reduction in preventing retinopathy of prematurity. N Engl J Med. 1998;338(22):157276
5. ReynoldsJD, Dobson V, Quinn GE, et al; CRYO-ROP and LIGHT-ROP Cooperative Study Groups. Evidence-based screening criteria for retinopathy of prematurity: natural history data from the CRYO-ROP and LIGHTROP studies. Arch Ophthalmol. 2002;120 (11):147076
6. EarlyTreatment for Retinopathy of Prematurity CooperativeGroup. Revised indications for the treatment of retinopathy of prematurity. Results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121(12):168496
7. Screening examination of premature infants for retinopathy of prematurity. A joint statement of the American Academy of Pediatric, the American Association for Pediatric Ophthalmology and Strabismus, and the American Academy of Ophthalmology. Ophthalmology. 1997;104:888-89
8. An International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol. 2005;123(7):991-9.
9.Gilbert C, Foster A. Childhood blindness in the context of VISION 2020the right to sight. Bull World Health Organ. 2001;79(3):227 32.
10. Özcan A, Soylu M, Demircan N, Satar M, Narlı N.Prematüreretinopatisi gelişimindeki risk faktörleri ve tedavi sonuçları. Türk Oftalmol. Gaz. 1997;27: 290-94.
11. FleckBW, McIntosh N. Pathogenesis of retinopathy of prematurity and possible preventive strategies. Early Hum Dev. 2008;84(2):83-8
12. Yalaz M, Arslanoğlu S, Erakgün ET, Yurtsever SN, Akisu M, Akkın C, Menteş J, Kültürsay N. Prematüre Retinopatisi Risk Faktörleri ve Koruyucu Önlemler. Turk.Klinikleri J. Pediatr 2003;12(1):1-8
13. Sönmez K, Özcan PY, İlhan B, Altıntaş AK. Yenidoğan Yoğun Bakım Ünitesindeki Bebeklerde Prematüre Retinopatisi Sıklığı, Gelişiminde Etkili Risk Faktörleri ve Tedavi Sonuçları. Ret-Vit. 2011;19(4):225-30.
14. Öner A, Özkırış A, Güneş T, Karaküçük S, Erkılıç K, Çetin N. Prematüre Retinopatisi: 2 yıllık tarama sonuçlarımız. Erciyes Tip Derg. 2005;27(3):104-9.
15. Kavurt S, Yücel H, Hekimoğlu E, Baş AY, Demirel N, Türkbay D. Prematüre retinopatisi gelişen olgularda risk faktörlerinin değerlendirilmesi. Çocuk SagligiHast. Derg. 2012;55:125-31.
16. Özbek E, Genel F, Atlıhan F, Güngör İ, Malatyalı R, Menteş J, Berk T. Yenidoğan yo- ğun bakım ünitemizde prematüre retinopatisiinsidansı, risk faktörleri ve izlem sonuçları. Behcet Uz CocukHast. Derg. 2011; 1(1):7-12
17. PalmerEA, Flynn JT, Hardy RJ, et al. Incidenceandearlycourse of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1991;98:1628-40.
18. Scalif-Delfos NE, CatsBP. Retinopathy of prematurity: the continuing threattovision in preterminfants . Dutch survey from 1986 to 1994. Acta Ophthalmol Scan 1997;75:72-75
19. FledeliusHC, KjerB.Surveillanceforretinopathy of prematurity in a Danishcountry. Epidemiological experience over 20 years. ActaOphthalmolScand. 2004;82:38-41
20. Charan R, DograMR, Gupta A, et al. Theincidence of retinopathy of prematurity in a neonatal care unit. Indian J Ophthalmol. 1995;43:123-26.
21. PhanMH, NguyenPN, ReynoldsJD. Incidence and severity of retinopathy of prematurity in Vietnam, a developing middle-income country. J Pediatr Ophthalmol Strabismus. 2003;40:208-12.
22. Mintz-Hittner HA, KuffelRRJr. Intravitrealinjection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I orposteriorzone II. Retina. 2008;28(6):831-8
23. Mintz-Hittner HA. Treatment of retinopathy of prematurity with vascular endothelial growth factor in hibitors. Early Hum Dev. 2012;88(12):937-41
24. WuWC, KuoHK, YehPT, Yang CM, Lai CC, Chen SN. An updatedstudy of theuse of bevacizumab in thetreatment of patientswithprethresh old retinopathy of prematurity in Taiwan. Am J Ophthalmol. 2013;155(1):150- 58
25. HarderBC, vonBaltz S, SchlichtenbredeFC, JonasJB. Early refractive outcome after in travitreous bevacizumab for retinopathy of prematurity. Arch Ophthalmol. 2012;130(6):800-1